Scarica l'app Stockscreener
119.72
10.40%
-13.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$133.61
Aprire:
$125.99
Volume 24 ore:
4.45M
Relative Volume:
2.38
Capitalizzazione di mercato:
$18.29B
Reddito:
$4.29B
Utile/perdita netta:
$703.00M
Rapporto P/E:
26.82
EPS:
4.4635
Flusso di cassa netto:
$993.00M
1 W Prestazione:
-17.33%
1M Prestazione:
-18.62%
6M Prestazione:
+26.78%
1 anno Prestazione:
-2.51%
Intervallo 1D:
$117.67
$128.16
Intervallo di 1 settimana:
$117.67
$143.56
Portata 52W:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
119.72 | 20.42B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
542.83 | 203.77B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.61 | 152.51B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
644.61 | 51.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
129.58 | 36.75B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
187.49 | 30.69B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Could Nvidia Be the Best Way to Play the AI Boom in 2026? - The Motley Fool
Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus - TechStock²
Illumina Enters Oversold Territory (ILMN) - Nasdaq
UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating - marketscreener.com
Molina Healthcare, Coty, Illumina, Amazon and other big stocks moving lower in Friday's pre-market session - MSN
Illumina, Inc. (NASDAQ:ILMN) Q4 2025 Earnings Call Transcript - Insider Monkey
Illumina, Inc.'s (NASDAQ:ILMN) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Illumina revenue up 5% to USD 1.16B in Q4 2025 - Medical Buyer
ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum - Yahoo Finance
Illumina Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Illumina beats Q4 2025 EPS forecast by 10.66% - Investing.com Canada
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances - Investing.com
Illumina Inc (NASDAQ:ILMN) Stock Falls Despite Q4 Earnings Beat on Cautious 2026 Outlook - Chartmill
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates - Nasdaq
Illumina: Q4 Earnings Snapshot - kens5.com
Illumina shares tumble as flat revenue disappoints investors By Investing.com - Investing.com
Illumina Inc. Q4 Profit Advances - Nasdaq
Illumina Q4 Non-GAAP Earnings, Revenue Rise; 2026 Outlook Set - marketscreener.com
Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025 - Yahoo Finance
Illumina Q4 Earnings Summary & Key Takeaways - Benzinga
Earnings Flash (ILMN) Illumina, Inc. Reports Q4 Revenue $1.16B, vs. FactSet Est of $1.12B - marketscreener.com
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 - PR Newswire
Illumina earnings loom as investors seek clarity on 2026 outlook By Investing.com - au.investing.com
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics - Yahoo Finance
Multi-Omics Market Set for Explosive Growth to USD 33.25 Billion - openPR.com
San Diego Zoo’s Frozen Zoo Gets Genomic Boost - 101.5 KGB
Synthetic Biology Market Set for Explosive Growth to USD 67.47 - openPR.com
Mediolanum International Funds Ltd Makes New $914,000 Investment in Illumina, Inc. $ILMN - MarketBeat
Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What Catalysts Are Shifting The Illumina (ILMN) Story For 2026 And Beyond - Yahoo Finance
Illumina, Inc. and the San Diego Zoo Wildlife Alliance Partner to Sequence the Frozen Zoo - marketscreener.com
Illumina Partners with San Diego Zoo for Genomic Sequencing of Endangered Species - intellectia.ai
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally - Sahm
WCM Investment Management LLC Has $384.17 Million Position in Illumina, Inc. $ILMN - MarketBeat
Bioinformatics Market to Witness Massive Growth by 2033: - openPR.com
Mapping the future of whole-genome sequencing with Illumina constellation technology - Illumina
Video: UK Festival of Genomics & Biodata 2026 - Illumina
PacBio sells short-read DNA sequencing assets to Illumina for $48.1m - Investing.com Canada
Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina - marketscreener.com
PacBio (PACB) Finalizes Asset Sale to Illumina, Secures $48.1 Mi - GuruFocus
Illumina completes acquisition of SomaLogic - marketscreener.com
Illumina buys SomaLogic in bid to expand proteomics reach - The Pharma Letter
ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance - TradingView
Pacific Biosciences of California Signs Asset Purchase Agreement With Illumina Cambridge - TradingView
Does CMS Backing of TruSight Oncology Recast Illumina’s (ILMN) Clinical Genomics Potential? - simplywall.st
PacBio Completes Sale of Short-Read Sequencing Assets to Illumina for $48.1 Million - Quiver Quantitative
Illumina acquires SomaLogic - Medical Buyer
Thrivent Financial for Lutherans Sells 38,212 Shares of Illumina, Inc. $ILMN - MarketBeat
Exosome Research Market to Witness Stunning Growth 2026-2033 - openPR.com
DNA Sequencing Market Covering Prime Factors and Competitive - openPR.com
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):